• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Role of Increased n-acetylaspartate Levels in Cancer
Conclusion: These findings indicate that the NAA pathway has a prominent role in promoting tumor growth and represents a valuable target for anticancer therapy. Altered energy metabolism is a hallmark of cancer (1). Proliferating cancer cells have much greater metabolic requirements than nonproliferating differentiated cells (2,3). Moreover, altered cancer metabolism elevates unique metabolic intermediates, which can promote cancer survival and progression (4,5). Furthermore, emerging evidence suggests that proliferating cancer cells exploit alternative metabolic pathways to meet their high demand for energy and to accumul...
Source: JNCI - January 26, 2016 Category: Cancer & Oncology Authors: Zand, B., Previs, R. A., Zacharias, N. M., Rupaimoole, R., Mitamura, T., Nagaraja, A. S., Guindani, M., Dalton, H. J., Yang, L., Baddour, J., Achreja, A., Hu, W., Pecot, C. V., Ivan, C., Wu, S. Y., McCullough, C. R., Gharpure, K. M., Shoshan, E., Pradeep, Tags: Article Source Type: research

Therapeutic Targeting of Integrin {alpha}v{beta}6 in Breast Cancer
Conclusions Targeting αvβ6 with 264RAD alone or in combination with trastuzumab may provide a novel therapy for treating high-risk and trastuzumab-resistant breast cancer patients.
Source: JNCI - June 28, 2014 Category: Cancer & Oncology Authors: Moore, K. M., Thomas, G. J., Duffy, S. W., Warwick, J., Gabe, R., Chou, P., Ellis, I. O., Green, A. R., Haider, S., Brouilette, K., Saha, A., Vallath, S., Bowen, R., Chelala, C., Eccles, D., Tapper, W. J., Thompson, A. M., Quinlan, P., Jordan, L., Gillett Tags: Article Source Type: research

SMYD3 as an Oncogenic Driver in Prostate Cancer by Stimulation of Androgen Receptor Transcription
Conclusions SMYD3 promotes prostate tumorigenesis and mediates epigenetic upregulation of AR expression.
Source: JNCI - November 19, 2013 Category: Cancer & Oncology Authors: Liu, C., Wang, C., Wang, K., Liu, L., Shen, Q., Yan, K., Sun, X., Chen, J., Liu, J., Ren, H., Liu, H., Xu, Z., Hu, S., Xu, D., Fan, Y. Tags: Article Source Type: research

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin {beta}3-Src Pathway
Conclusions Increased Src activation through integrin αβ3 confers considerable resistance against anti–IGF-1R mAb-based therapies in HNSCC and NSCLC cells. Dual targeting of the IGF-1R pathway and collateral integrin β3–Src signaling module may override this resistance.
Source: JNCI - October 15, 2013 Category: Cancer & Oncology Authors: Shin, D. H., Lee, H.-J., Min, H.-Y., Choi, S. P., Lee, M.-S., Lee, J. W., Johnson, F. M., Mehta, K., Lippman, S. M., Glisson, B. S., Lee, H.-Y. Tags: Article Source Type: research